Results 101 to 110 of about 8,529 (239)

A PBPK model for PRRT with [177Lu]Lu-DOTA-TATE: Comparison of model implementations in SAAM II and MATLAB/SimBiology

open access: yes
Physiologically based pharmacokinetic (PBPK) models offer the ability to simulate and predict the biodistribution of radiopharmaceuticals and have the potential to enable individualised treatment planning in molecular radiotherapy.
Sjögreen Gleisner, Katarina   +6 more
core   +2 more sources

Prediction of Monoclonal Antibody Pharmacokinetics in Pediatric Populations Using PBPK Modeling and Simulation

open access: yesPharmaceutics
Background: Accurately determining pediatric dosing is essential prior to initiating clinical trials or administering medications in routine clinical settings. In children, ethical considerations demand careful evaluation of both safety and effectiveness.
Chiara Zunino   +4 more
doaj   +1 more source

Workflow of the rabbit PBPK/TK model development.

open access: yes, 2018
Starting with a generic mammalian PBPK model on top, rabbit specific physiology parameters are added (first level). Next, physicochemistry from a compound (second level), followed by information regarding active processes (third level) are introduced ...
Sebastian Schneckener (436626)   +4 more
core   +1 more source

Evaluating Thiram‐Induced Embryotoxicity Using Integrated In Silico, In Vitro, and Transcriptomic Approaches

open access: yesEnvironmental Toxicology, EarlyView.
ABSTRACT Long‐term exposure to low‐dose food contact materials (FCMs) has raised concerns regarding developmental toxicity. In the present study, we prioritized FCMs with potential developmental toxicity using a weight‐of‐evidence computational model, which predicted 127 chemicals to be of high concern.
Chia‐Chi Ho   +7 more
wiley   +1 more source

The model schema of the mechanistically based PBPK/PD model details at the liver.

open access: yes, 2019
The IFN-α is cleared via the binding to the respective receptors in the liver. The binding of IFN-α to the IFNAR2 and IFNAR1 takes place in the interstitium of the liver (M1-M5), hence activating the JAK/STAT pathway leading to the activation of mRNAc of
Jörg Lippert (124210)   +7 more
core   +1 more source

Microplastics and the Endocrine–Metabolic Interface: Novel Diagnostic Tools Targeting Thyroid–Adipose Axis

open access: yesEnvironmental Toxicology, EarlyView.
ABSTRACT Microplastics (MPs) have been identified as major environmental contaminants that can affect organisms directly and act as carriers of particles and chemical additives, thereby aggravating endocrine networks that coordinate metabolic homeostasis.
Sunday Amos Onikanni   +10 more
wiley   +1 more source

A physiologically-based pharmacokinetic model of oseltamivir phosphate and its carboxylate metabolite for rats and humans

open access: yesADMET and DMPK, 2019
Oseltamivir phosphate (OP, Tamiflu®) is a widely used prodrug for the treatment of influenza viral infections. Orally administered OP is rapidly hydrolyzed by the carboxylesterases in animals to oseltamivir carboxylate (OC), a potent influenza virus ...
Guanghua Gao   +4 more
doaj   +1 more source

EuroMix PBPK model for combined exposures

open access: yes, 2019
In this paper documents the structure and default parameter values of the EuroMix PBPK model implemented in the MCRA platform for rats and humans. A version allowing apportionment of results by exposure routes is also described. Finally, the extensions needed to describe pharmacokinetic interactions between pairs or triplets of substance are discussed.
Bois, F.Y., Tebby, C., Brochot, C.
openaire   +2 more sources

Development of a Physiologically Based Pharmacokinetic (PBPK) Model for the Inhalational Route

open access: yes, 2022
S.A38, Abstract O-111For the pre‐clinical development of new drugs and for safety assessment of chemicals PBPK‐modeling is an attractive tool.
Escher, Sylvia E.   +5 more
core  

Identification of drug repurposing candidates for the treatment of polycystic kidney disease

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end‐stage renal disease with limited treatment options. Drug repurposing offers a promising strategy to find effective treatments. Experimental Approach We identified birinapant, bardoxolone methyl and salicylic acid as repurposing candidates for ADPKD and
Alina Meyer   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy